Table 3.
Comparison between correctly classified versus misclassified CTs in the intramural test subset
| CTs with PDA (n=409) | Control CTs (n=829) | |||||
|---|---|---|---|---|---|---|
| Correctly classified (n=360) | Misclassified (n=49) | P-value | Correctly classified (n=783) | Misclassified (n=46) | P-value | |
| Males: Females | 1.2:1 | 1:1 | 0.83 | 0.8:1 | 1.2:1 | 0.31 |
| Mean age (SD) (years) | 66.7 (9.9) | 65.4 (10.4) | 0.38 | 55.3 (15.8) | 63.9 (14.1) | <0.001 |
| Slice thickness (mm) | 0.86 | 0.47 | ||||
| 0–1.25 | 151 (42%) | 23 (47%) | 277 (35%) | 19 (41%) | ||
| 1.25–3.0 | 130 (36%) | 17 (35%) | 488 (62%) | 25 (54%) | ||
| 3.0–5.0 | 79 (22%) | 10 (18%) | 18 (2%) | 2 (4%) | ||
| CT vendor | 0.75 | 0.06 | ||||
| Siemens | 210 (58%) | 30 (62%) | 694 (88%) | 37 (80%) | ||
| GE | 105 (29%) | 15 (30%) | 67 (9%) | 9 (20%) | ||
| Toshiba | 39 (11%) | 3 (6%) | 21 (3%) | 0 (0%) | ||
| Philips | 6 (2%) | 1 (2%) | 1 (0.1%) | 0 (0%) | ||
| Tumor location | 0.14 | |||||
| Head | 259 (72%) | 33 (68%) | .. | .. | .. | |
| Body | 43 (12%) | 3 (6%) | .. | .. | .. | |
| Tail | 54 (15%) | 13 (26%) | .. | .. | .. | |
| Predominantly extrapancreatic | 4 (1%) | 0 (0%) | .. | .. | .. | |
| Ancillary features | ||||||
| MPD dilation and/or cut off | 281 (78%) | 22 (45%) | <0.01 | .. | .. | .. |
| CBD dilation and/or cutoff | 178 (49%) | 18 (37%) | 0.13 | .. | .. | .. |
| Pancreatic atrophy | 231 (64%) | 22 (45%) | 0.01 | .. | .. | .. |
| Tumor Size (cm) | 0.001 | |||||
| Mean (SD) | 3.5 (1.3) | 2.8 (0.8) | .. | .. | .. | |
| Median | 3.3 | 2.8 | .. | .. | .. | |
| Tumor stage | 0.04 | |||||
| 1 | 28 (8%) | 7 (14%) | .. | .. | .. | |
| 2 | 252 (70%) | 39 (80%) | .. | .. | .. | |
| 3 | 57 (16%) | 3 (6%) | .. | .. | .. | |
| 4 | 23 (6%) | 0 (0%) | .. | .. | .. | |
| Isodense tumors | 71 (20%) | 16 (33%) | 0.06 | .. | .. | .. |